May 10, 2021
published at 7:07 AMReuters
General view shows the laboratories of BioNTech at their Covid-19 vaccine production facility as the spread of the coronavirus disease (Covid-19) continues, in Marburg, Germany, on March 27, 2021.
Reuters
BERLIN - BioNTech said on Monday (May 10) it plans to set up a regional headquarters and build a new manufacturing site for its vaccines based on messenger RNA technology (mRNA) in Singapore, in the latest move to expand its production network.
The biotech company said the Singapore production facility will have an estimated annual capacity of several hundred million doses of mRNA-based vaccines depending on the specific type, once it is operational in 2023.
10 May 2021 - 10:18
A person receives a dose of the Pfizer-BioNTech COVID-19 vaccine in the Central Mosque in Ehrenfeld suburb, amid the coronavirus disease (COVID-19) pandemic, in Cologne, Germany, May 8, 2021. Reuters/Thilo Schmuelgen
Bloomberg
German vaccine developer BioNTech SE selected Singapore as its Southeast Asia headquarters and first Asia-Pacific hub, giving a boost to supply of an mRNA vaccine that’s been extraordinarily effective in fighting Covid-19.
The production site could be operational as early as 2023 and will create as many as 80 jobs in Singapore, the company said in a statement Monday.
The Mainz, Germany-based BioNTech said the planned state-of-the-art manufacturing site will support global supply of mRNA-based vaccines and therapeutics and provide rapid-response options for Southeast Asia against potential future pandemic threats.
BioNTech to build first mRNA manufacturing facility in Singapore
By IANS |
Published on
Mon, May 10 2021 15:33 IST |
6 Views
BioNTech to build first mRNA manufacturing facility in Singapore. Image Source: IANS News
Berlin, May 10 : German biotechnology company BioNTech on Monday announced plans to expand its global footprint to Asia by building its first mRNA manufacturing facility in Singapore.
The Covid vaccine maker will establish its regional headquarters for Southeast Asia in Singapore, later this year, it said in a statement. The facility will be operational as early as 2023, it added.
The fully integrated mRNA manufacturing facility will provide regional and global supply capacity of BioNTech s growing pipeline of mRNA-based product candidates. It will be equipped to produce a range of novel mRNA vaccines and therapeutics for infectious diseases and cancer.
Vaccine maker BioNTech to set up regional headquarters, manufacturing site in Singapore
BioNTech s Singapore office is expected to be operational in 2023 and will create at least 80 jobs. Photo: Reuters The Straits Times The Straits Times
BioNTech, the vaccine maker that has partnered with Pfizer on its Covid-19 shot, will be designating Singapore as its regional headquarters for South-east Asia, and will set up an mRNA manufacturing facility here.
It plans to open its Singapore office and start the construction of the manufacturing facility in 2021, subject to planning approval. The site is expected to be operational in 2023 and will create at least 80 jobs, the German company said on Monday (May 10).
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
BioNTech Announces First Quarter 2021 Financial Results and Corporate Update
BioNTech SEMay 10, 2021 GMT
More than 450 million doses of BNT162b2 supplied to 91 countries or territories worldwide as of May 6, 2021
Signed agreements for over 1.8 billion doses of BNT162b2 in 2021 and first contracts signed for periods 2022 and beyond
Announced planned expansion of global footprint to Asia with establishment of first regional headquarters for south east Asia in Singapore, including a fully-integrated and state-of-the art mRNA manufacturing facility
In oncology, a first-in-human Phase 1 trial started for the neoantigen-targeting T cell therapy, BNT221. The development of BioNTech’s oncology pipeline has continued to accelerate with 14 product candidates now in 15 ongoing trials